ilc-dover-news
-
Ingersoll Rand to Acquire ILC Dover to Expand Presence in Life Sciences
3/25/2024
Ingersoll Rand Inc. (NYSE:IR), a global provider of mission-critical flow creation and industrial solutions, has entered into an agreement to acquire ILC Dover (“ILC”) from New Mountain Capital, LLC, a leading growth-oriented investment firm with approximately $50 billion in assets under management. The deal includes an upfront cash purchase price of approximately $2.325 billion and an earnout tied to the achievement of select operating efficiency metrics in 2024. At its maximum payout, the earnout
-
ILC Dover Secures North Carolina Facility To Expand Dry Repack Capabilities And Build Out cGMP Raw Materials Portfolio
1/19/2023
ILC Dover LP, specializing in innovative single-use solutions for biotherapeutics and pharmaceutical processing, has opened a new facility in Lillington, North Carolina to offer pre-filled trusted-weight cGMP raw materials for the growing biomanufacturing market. As a solutions provider for the expanding life sciences industry, ILC Dover continues to meet market demands by developing comprehensive solutions customized to customers' unique needs and end applications.
-
ILC Dover Announces New Multi-Compendial Water For Injection Solutions For Biopharma And Cell & Gene Therapy Market
8/1/2022
ILC Dover, specializing in innovative single-use solutions for biotherapeutics and pharmaceutical processing, announced the launch of Water for Injection (WFI) for the biotherapeutics market.
-
Solving API Manufacturing Challenges With Flexible Containment Webinar Announced for June 21
6/7/2022
Are you concerned about operational safety and efficiency during API manufacturing? This webinar discusses some of the common challenges faced in handling powders during HAPI/API manufacturing. Key strategies to mitigate risks associated with these issues will be shared including how flexible containment solutions can optimize powder handling during chemical synthesis.
-
ILC Dover Plans To Build New Manufacturing Facility In Poland To Meet Biopharma Industry Needs
5/9/2022
ILC Dover LP, specializing in innovative single-use and chemical workflow solutions for biotherapeutics and pharmaceutical processing, announced plans to break ground on a new 90,000 sq ft manufacturing site located in Gliwice, Poland in response to continued strong growth within its life sciences business. The state-of-the-art facility equipped with 20,000 sq ft of ISO Class 7 cleanroom capability will manufacture initially single-use powder bags, single-use liquid bags, and single-use fluid transfer assemblies. The new site will provide redundant supply capabilities, reduce the lead times for its European and Asian customers and manufacturing will be consistent with the Company’s global quality system.
-
ILC Dover Announces Single-Use Bags Ideal For Biopharma And Cell/Gene Therapy Drug Manufacturers
3/29/2022
ILC Dover LP (“ILC Dover” or the “Company”), specializing in innovative single-use solutions for biotherapeutics and pharmaceutical processing, announced its launch of liquid single-use bioprocessing bags, representing the first of many new products for handling and supply of sterile liquids for the biotherapeutics market.
-
ILC Dover Announces Acquisition Of KSE Scientific To Assist Biopharma, Med Device And Cell & Gene Markets
12/16/2021
ILC Dover, Inc., a leading designer and manufacturer of high-performance materials for life critical and primarily life sciences-based applications, today announced the acquisition of KSE Scientific (“KSE”), a sterile solutions manufacturer which specializes in the production of Water for Injection (WFI) and related media and buffer solutions for biopharma, cell & gene therapy, tissue banking and medical device end-markets.
-
ILC Dover Announces April 13th Webinar For Recently Developed Aseptic Isolator System
4/7/2021
With the development of ILC Dover’s new Aseptic Isolator system new opportunities have opened up for many organizations who were previously able to conduct fill finish activities due to facility restraints or expensive closed barrier systems.
-
ILC Dover Expands Containment Technologies With Acquisition Of UK-Based Solo Containment
9/9/2020
ILC Dover, Inc. (“ILC Dover” or the “Company”), a world leader in the design and production of single-use flexible solutions for pharmaceutical and biopharmaceutical manufacturing, today announced the acquisition of Solo Containment, Ltd. (“Solo”), a specialist manufacturer of flexible film isolators based in the United Kingdom. The acquisition will grow ILC Dover’s global pharmaceutical and biopharmaceutical business, expanding its solutions for high containment and powder transfer to include aseptic flexible isolators, among others.
-
ILC Dover Announces September 17 Webinar Gaining Value With Single Use Containment For Contract Manufacturers
9/3/2019
CMO and CDMO facilities have experienced fast paced growth and with more potent compounds planned for launch in the future the good times will continue. There are unique problems with growth for these contract facilities and many have to do with the controls required to assure proper containment of compounds in a multi-use facility. Containment is critical to assure personnel are not exposed to the affects of the drugs and to mitigate issues with cross contamination. These additional controls require greater attention to SOP’s particularly for cleaning and validation. These cleaning procedures reduce the uptime of equipment or process suites then limiting the facility to take on more campaigns and grow faster. This is where single use containment can expedite the changeover in campaigns while still providing the needed controls.